Bli medlem
Bli medlem

Du är här

2015-04-24

Biotie Therapies Oyj: Notification according to Chapter 9, Section 5 of the Finnish Securities Markets Act

BIOTIE THERAPIES CORP. STOCK EXCHANGE RELEASE 24 April 2015 at 1.17 p.m.

Notification according to Chapter 9, Section 5 of the Finnish Securities
Markets Act

Biotie Therapies Corp. (the "Company" or "Biotie") has received a notification
in accordance with Chapter 9, Section 5 of the Finnish Securities Markets Act
from Mr. Samuel D. Isaly on behalf of himself, OrbiMed Advisors LLC, OrbiMed
Capital GP V LLC and OrbiMed Private Investments V, LP (the "Investor").

According to the notification, Samuel D. Isaly is the managing member of and
owner of a controlling interest in OrbiMed Advisors LLC, which is the sole
managing member of OrbiMed Capital GP V LLC, which is the general partner of
OrbiMed Private Investments V, LP. According to the notification, neither
Samuel D. Isaly nor any other entity under his control, other than OrbiMed
Private Investments V, LP, holds any shares or securities entitling to shares
in the Company. The notification concerns an arrangement that, if realized,
would result in the below described changes in share ownership.

The notification relates to the subscription agreement entered into on 23
April 2015 between Biotie and certain investors which is described in more
detail in the stock exchange release issued by the Company on 23 April 2015.
The said investors have agreed to invest in the Company by means of
subscribing for convertible promissory notes ("Convertible Notes") and other
equity-based instruments ("Warrants"). The issue and subscription of the
Convertible Notes and Warrants is conditional, among other things, on the
granting of necessary authorizations and election of new Board members by an
Annual General Meeting of Biotie to be held on 26 May 2015.

The convertible loan to be represented by the Convertible Notes can be
converted into new shares in the Company by their holders at any time prior
to the repayment of the Convertible Notes, which is scheduled to occur on or
after 1 May 2035. Further, the Convertible Notes would automatically convert
into new shares in the Company upon completion of a proposed US public
offering and listing on the Nasdaq Global Market of American Depositary
Receipts representing the Company's shares. If the US public offering would
not take place by 1 May 2016, the Company can force the conversion of the
Convertible Notes at any time thereafter. The Warrants will entitle to
subscribe for shares in the Company until 1 November 2020.

According to the notification, should the Convertible Notes and Warrants be
issued to the Investor, their conversion and exercise in full would result in
shareholding in the Company as described below:

---------------------------------------------------------------------------------------------------------------------------------
| Number of shares and voting rights (%) of shares and voting rights |
| Shares and voting rights currently held 0 0 |
| Shares and voting rights after full conversion and exercise |
| Shares that may be subscribed based on Convertible Notes 51,944,444 6.31 |
| Shares that may be subscribed based on Warrants 51,944,444 6.31 |
| Total 103,888,888 12.63 |
| |
| TOTAL HOLDINGS 103,888,888 12.63 |
---------------------------------------------------------------------------------------------------------------------------------
According to the notification, the total number of shares and votes used above
is 822,634,842, which has been calculated as (a) the current total number of
shares and votes as published by the Company in accordance with Chapter 8,
Section 6 of the Securities Markets Act, added with (b) the total number of
shares and votes following full conversion and exercise of the Convertible
Notes and Warrants, assuming no other new shares are issued by the Company.
At the date of this release, the number of shares in Biotie Therapies Corp.
amounts to 455,968,174, of which 3,366,690 shares are held by the Company and
its subsidiaries.

In Turku, 24 April 2015

Biotie Therapies Corp.

Timo Veromaa
President and CEO

For further information, please contact:

David Cook, CFO

Tel. +358 2 2748 900, e-mail: david.cook@biotie.com

DISTRIBUTION:

NASDAQ OMX Helsinki Ltd
Main Media
www.biotie.com

---------------------------------------

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Biotie Therapies Oyj via Globenewswire

HUG#1914554

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.